WS
SER icon

Wedbush Securities’s Serina Therapeutics SER Stock Holding History

Wedbush Securities’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,931
Closed -$55K – 985
2020
Q3 		$55K Buy
+1,931
New +$68.9K 0.01% 875

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wedbush Securities's SER Position: Q4 2020 in Review

Wedbush Securities sold out of Serina Therapeutics (SER) in Q4 2020, closing a stake of 1,931 shares — an estimated $55K sold.

Wedbush Securities first reported a position in SER in Q3 2020 and held it in 1 quarter. The position peaked at $55K in Q3 2020. 37 funds tracked by Wall St. Rank hold SER as of Q4 2020.

  • Wedbush Securities reported no remaining Serina Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 1,931 Serina Therapeutics shares in Q4 2020, an estimated $55K.
  • Wedbush Securities first reported a position in Serina Therapeutics in Q3 2020 and held it in 1 quarter.
  • Wedbush Securities's Serina Therapeutics position peaked at $55K in Q3 2020.
  • 37 funds tracked by Wall St. Rank held Serina Therapeutics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.